Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¸°­¾Ï¿¡¼­ ¸²ÇÁ°üÇü¼º ÀÎÀÚÀÇ ¹ßÇö¿¡ °üÇÑ ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿¬±¸

Immunohistochemical Study on Expression of Lymphangiogenic Factors in Oral Cancer

¹Ú¿µ¿í, ±Ç±¤ÁØ, ÀÌÁ¾¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿µ¿í ( Park Young-Wook ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç
±Ç±¤ÁØ ( Kwon Kwang-Jun ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç
ÀÌÁ¾¿ø ( Lee Jong-Won ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç

Abstract


Background and Purpose: Vascular endothelial growth factor (VEGF)-C and VEGF receptor (VEGFR)-3 are involved in tumor lymphangiogenesis. Oral mucosal squamous cell carcinoma (OMSCC) preferentially metastasizes to cervical lymph nodes, so we investigated the expression and distribution of VEGFR-3 signaling proteins in OMSCC.

Materials and Methods: Tissue samples of 18 OMSCC, 10 oral mucosal leukoplakia, and 3 normal oral mucosa were evaluated for expression of VEGF-C, VEGF-D, and VEGFR-3 by immunohistochemical staining. The presence of lymphatic vessels was determined using D2-40 staining, by which we also measured lymphatic vessel density (LVD).

Results: 72% (13/18) and 56% (10/18) of tissue samples showed VEGF-C and VEGF-D immunopositivity in tumor cells and tumor-associated endothelial cells. VEGFR-3 was also expressed in most of OMSCC, which was up-regulated when compared with normal mucosa or with leukoplakia. Furthermore, LVD was higher in OMSCC than in leukoplakia.

Conclusion: Taken together, our results suggest that autocrine activation of lymphatic endothelial cell via VEGFR-3 by VEGF-C and/or VEGF-D could be involved in progression of OMSCC. Therefore, VEGF-C/VEGFR-3 signaling pathway can be a molecular target for anti-metastatic therapy in OMSCC.

Å°¿öµå

Oral mucosal squamous cell carcinoma;Lymphangiogenesis;Lymphatic vessel density

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed